HOUSTON, TX - June 30, 2025 (NEWMEDIAWIRE) - Neutra Life Sciences, a newly launched Site Management Organization (SMO) and wholly owned subsidiary of Neutra Corp (OTC: NTRR), is proud to announce a strong and promising start to operations in Q1 2025. Founded on the success of a pilot program personally funded by its CEO in 2024, the company has already achieved positive operational cash flow in under six months, signaling a strong market position and operational efficiency from the outset.
With a mission to become the leading SMO in the clinical research industry, Neutra Life Sciences is focused on building a robust, multi-specialty site network that accelerates the delivery of high-quality clinical trials. Since officially launching, the company has grown from a single pilot site to a network of four clinical research sites - each with active research capabilities to support Phase Ib through Phase IV Trials in the following specialties:
- Pediatrics
- Pediatric Pulmonology
- Family Medicine
- Urgent Care
- Optometry
This specialty mix positions Neutra Life Sciences as a rapidly expanding, innovation-driven SMO capable of supporting complex, late-phase trials across key therapeutic areas.
Earlier this year, Neutra closed Joint Venture partnerships with several clinical sites, expanding the company’s infrastructure to conduct Phase 1b through Phase 4 research. These partnerships represent a key part of Neutra's strategy: to grow organically while forming strategic alliances that add long-term value and increase trial capacity.
“In a highly competitive and often fragmented SMO landscape, we're proving that intentional growth and diversified specialties can drive meaningful change for sponsors, CROs, and most importantly, patients,” said Sydney Jim, CEO of Neutra Corp. “This allows us to be able to build and scale without sacrificing quality, site performance, or patient care.”
The company’s trajectory is especially noteworthy when compared to industry benchmarks. In 2023, a 17-site SMO founded in 2017 was acquired for nearly $300 million, with only three active specialties. In contrast, Neutra has established a dynamic, specialty-rich network in under a year and is actively advancing its growth strategy.
Neutra Life Sciences is continuing to expand with multiple additional sites and medical specialties already in development. Each new site will be developed through intentional, organic growth - an approach that may take time, but is expected to prove far more profitable and sustainable in the long run. The company is expected to bring on two to three additional specialties within this quarter, further strengthening its ability to serve a broader range of clinical trials and indications.
We are pleased to provide an update that we are in the due diligence phase of the potential strategic acquisition of Curaconnector.com, which could complement our current operations and enhance long-term shareholder value. While the outcome is not yet certain, we are evaluating the opportunity with a disciplined and strategic approach. Importantly, regardless of the acquisition’s outcome, our primary focus remains on the continued growth and development of Neutra Life Sciences, which we believe represents a significant driver of value and long-term performance. We remain committed to executing on our core strategy and will provide further updates as appropriate.
About Neutra Corp
Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being.
Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options.
Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information, and performance data, please visit https://www.neutrainc.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
Sydney Jim
307-228-1488
info@neutrainc.com
View the original release on www.newmediawire.com
